Mirna To Participate In Two Healthcare Investor Conferences In September

AUSTIN, Texas--(BUSINESS WIRE)--Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a pipeline of microRNA-based oncology therapeutics, today announced that senior management will participate in two upcoming healthcare investor conferences in September.

Conference Details:

Event: Citi's 11th Annual Biotech Conference
Date: September 7-8, 2016
Location: Boston, MA

Event: Rodman & Renshaw 18th Annual Global Investment Conference
Date/Time: Tuesday, September 13, 2016 at 10:25 a.m. ET
Location: New York, NY

The Rodman & Renshaw presentation will be webcast live and may be accessed from the Events & Presentations section of the Mirna Therapeutics website. An archived version of the webcast will be available for replay following the event.

About Mirna Therapeutics, Inc.

Mirna is a clinical stage biopharmaceutical company developing a pipeline of microRNA-based oncology therapeutics and is the first to bring a synthetic microRNA mimic into clinical development for the treatment of cancer. Mirna’s lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34), is being studied in a Phase 1 clinical trial which has included patients with primary liver cancer, advanced solid tumors and hematological malignancies. miR-34 is one of the most widely published microRNAs and is considered a key regulator of multiple oncogenes across key oncogenic pathways, with the capacity to regulate more than 30 different oncogenes and repress immune checkpoint signaling molecules, including PD-L1. The potential capacity to simultaneously affect multiple pathways and processes that are critical to cancer cell viability may make mimics of tumor suppressor microRNAs an important new class of anti-cancer agents. Mirna plans to develop MRX34 as a monotherapy and in combination with other therapies. The Company was founded in 2007 and is located in Austin, Texas.

For more information, visit www.mirnarx.com.